Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevudine Retreatment in Chronic Hepatitis B
NCT00362700Phase 2Terminated
- Sponsor
- Bukwang Pharmaceutical
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clevudine in Chronic Hepatitis B (CHB), sponsored by Bukwang Pharmaceutical. Primary endpoints: Change from baseline in HBV DNA (log10) and Safety (Laboratory tests, Adverse Events, Vital Signs, ECG). Started Jul 2003; status: terminated.
02
Drugs
clevudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00362700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362700.